September 1st, 2013
Pretreatment with Prasugrel Not Indicated in NSTEMI
Larry Husten, PHD
Pretreatment prasugrel for NSTEMI was not effective in the ACCOAST trial.
September 1st, 2013
ESC.13 Headquarters
CardioExchange Editors, Staff
Find all of our ESC.13 coverage here.
September 1st, 2013
Inside the ACCOAST Trial of Pretreatment Prasugrel
Gilles Montalescot, MD, PhD, John Ryan, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD
Gilles Montalescot, lead investigator of the ACCOAST trial, discusses why prasugrel pretreatment did not benefit patients with non–ST-segment elevation acute coronary syndromes.
September 1st, 2013
Is It Time to RE-ALIGN Our Thinking About Direct Thrombin Inhibitors?
Judith Andersen, AB, MD
Reflecting on the RE-ALIGN trial of dabigatran, Judith Andersen muses on the mechanisms of direct thrombin inhibitors.
September 1st, 2013
Positive Results for Edoxaban in VTE/PE
Larry Husten, PHD
Findings from the Hokusai-VTE trial of edoxaban
September 1st, 2013
A TASTE of Registry-Based Randomized Trials
Ole Frobert, MD, PhD and Harlan M. Krumholz, MD, SM
Ole Fröbert discusses his study group’s registry-based randomized trial of pre-PCI thrombus aspiration in STEMI patients.
September 1st, 2013
A Disruptive TASTE of the Future?
Larry Husten, PHD
Negative findings from a registry-based randomized trial of pre-PCI thrombus aspiration for STEMI patients
September 1st, 2013
Disappointing Results with Dabigatran for Mechanical Valves
Larry Husten, PHD
For more of our ESC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Despite being more durable than bioprosthetic valves, mechanical heart valves are often not chosen because of the requirement for […]